Treatment News : Statins Greatly Reduce Risk of Death in HIV Cohort Study

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 5, 2011

Statins Greatly Reduce Risk of Death in HIV Cohort Study

Taking a cholesterol-lowering statin, combined with antiretroviral (ARV) therapy, further reduced the risk of death by 67 percent in a cohort of people living with HIV, according to a new report published by PLoS One. Though the data are from an observational cohort study and need to be confirmed in a prospective clinical trial, the results add to a growing body of evidence supporting therapeutic strategies aimed at minimizing inflammation in people living with HIV. 

HIV is associated with chronic inflammation and immune activation. Though ARV therapy reduces inflammation, it often fails to reduce markers of inflammation to levels seen in people not living with HIV or other chronic infections.

Statins, technically called HMG-coenzyme A reductase inhibitors, are typically used to lower harmful cholesterol levels, thereby reducing the risk of cardiovascular disease (CVD). But research suggests that their lipid-lowering activity in the body doesn’t fully explain their effect on CVD risk—statins also appear to reduce inflammation, which has also been shown to be a CVD risk factor.

Based on these observations, along with the fact that many people living with HIV require cholesterol-lowering drugs to manage the lipid gains that often accompany ARV treatment, statins remain a logical therapy to assess for disease-reducing and life-saving effects in HIV-positive people.

Richard Moore, John Bartlett and Joel Gallant, all of Johns Hopkins University School of Medicine in Baltimore, explored this possibility by evaluating patients enrolled in the Johns Hopkins HIV Clinical Cohort who achieved undetectable viral loads within six months of starting ARV treatment after January 1, 1998. Assessment was continued until death in patients who maintained undetectable viral loads, or until their viral loads became detectable again and went above 500.

Roughly 15 percent of the 1,538 individuals who qualified for the analysis took a statin. Two thirds of study participants were men. Those who took a statin tended to be somewhat older (46 versus 42 years old) and to have started ARV treatment with a higher CD4 cell count (270 versus 200 cells).

Of the 85 people who died during the average 1.5-year follow-up period, seven used statins, whereas 78 did not. Cancers, non-AIDS-defining infections, liver failure and CVD were the main causes of death.

After adjusting for a variety of factors—CD4 cell count, viral load, hemoglobin, cholesterol levels when ARV therapy was started, age, race, hepatitis coinfection, the length of ARV therapy and the different types of ARVs used—the risk of death among those using statins was a third of that seen among those who didn’t use a statin. This was highly statistically significant, meaning it wasn’t due to chance, and translated into a 67 percent reduction in the risk of death among those who used statins in combination with HIV-suppressive ARV treatment.

“In summary,” the researchers write, “we found that patients who maintained virologic suppression on effective [ARV treatment] appeared to derive additional survival benefit from the use of a statin. If additional observational data support this finding, a randomized clinical trial would be warranted to confirm this association.”

Search: statins, HMG-coenzyme A reductase inhibitors, death, mortality, survival, inflammation, antiretrovirals, ARV, Johns Hopkins, Moore, Bartlett, Galant

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.